Abstract:RON (recepteur d'origine nantais) and MET (hepatocyte growth factor receptor) are tyrosine kinase receptors. Various cancers have aberrant RON and MET expression and activation, which contribute to cancer cell proliferation, invasiveness, and metastasis. Here, we explored RON and MET expression in pancreatic cancer and their relationship with overall survival (OS) time, and evaluated their significance as therapeutic targets of tyrosine kinase inhibitors in pancreatic cancer. We enrolled 227 patients with pancreatic cancer in the study. RON and MET expression was analyzed by immunohistochemical staining. Four human pancreatic cancer cell lines expressing variable levels of RON or MET and four MET superfamily inhibitors (BMS777607, PHA665752, INCB28060, Tivantinib) were used. The effect of the four tyrosine kinase inhibitors on cell viability, migration, and apoptosis were determined using cell viability, scratch wound healing, and Caspase-Glo 3/7 assays. Cellular signaling was analyzed by immunoprecipitation and western blotting. The therapeutic efficacy of the tyrosine kinase inhibitors was determined with mouse xenograft pancreatic cancer models in vivo. There was wide aberrant RON and MET expression in the cancer tissues. In 227 pancreatic cancer samples, 33% had RON overexpression, 41% had MET overexpression, and 15.4% had RON and MET co-overexpression. RON and MET expression were highly correlated. RON and MET expression levels were significantly related to OS. Patients with RON and MET co-overexpression had poorer OS. BMS777607 and PHA665752 inhibited pancreatic cancer cell viability and migration, and promoted apoptosis by inhibiting RON and MET phosphorylation and further inhibiting the downstream signaling pathways in vitro. They also inhibited tumor growth and further inhibited phosphorylated (phosphor)-RON and phospho-MET expression in the mouse xenograft models in vivo effectively. INCB28060, which inhibits the MET signaling pathway alone, was not effective. RON and MET can be important indicators of prognosis in pancreatic cancer. Tyrosine kinase inhibitors targeting RON and MET in pancreatic cancer are a novel and potential approach for pancreatic cancer therapy.

Expression of CD151 c-Met, integrin alpha 3, alpha 6 and the prognostic significance in pancreatic ductal adenocarcinoma

Expression and Prognostic Significance of CD151, c-Met, and Integrin alpha3/alpha6 in Pancreatic Ductal Adenocarcinoma

Down-expression of CD36 in Pancreatic Adenocarcinoma and Its Correlation with Clinicopathological Features and Prognosis.

Glypican-3 and Krt19 Are Markers Associating with Metastasis and Poor Prognosis of Pancreatic Ductal Adenocarcinoma

Role of Overexpression of CD151 And/or C-Met in Predicting Prognosis of Hepatocellular Carcinoma

Prognostic Value of Programmed Cell Death Protein 1 Expression on CD8+ T Lymphocytes in Pancreatic Cancer

Clinical impact and prognostic value of CD 147 and MMP-7 expression in patients with pancreatic ductal adenocarcinoma

Protocadherin-1 Serves As a Prognostic Biomarker and Promotes Pancreatic Cancer Progression by Suppressing CD8+ T Cell Infiltration Through CCL5-CCR5 Axis.

Expression and clinical significance of hepatocyte growth factor receptor and epidermal growth factor receptor in pancreatic cancer

Over-Expression of C-Met Contributes to the Progression of Pancreatic Cancer

Aberrant RON and MET Co-overexpression As Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.

Clinical significance of xpression of HIF-1α and EMT related actors in pancreatic ductal adenocarcinoma

Clinical significance of expression of HIF-1α and EMTrelated factors in pancreatic ductal adenocarcinoma

Overexpression of CD151 As an Adverse Marker for Intrahepatic Cholangiocarcinoma Patients.

Expression of CD105 and D2-40 in pancreatic carcinoma and their clinical significance

The Clinical and Pathological Significance of Nectin-2 and Ddx3 Expression in Pancreatic Ductal Adenocarcinomas

Co-expression of CD133, CD44v6 and human tissue factor is associated with metastasis and poor prognosis in pancreatic carcinoma.

Molecular Characterization of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma: Potential Diagnostic and Prognostic Significance in Clinical Practice.

Expression and significant of EphA2、 EphrinAl and E-cadherin in pancreatic carcinoma

Prognostic Values of CD38+CD101+PD1+CD8+ T Cells in Pancreatic Cancer.

Study on the Expression and Clinical Significance of TGF-β_1 and CD105 in Pancreatic Carcinoma